Double-blind, randomized, placebo-controlled clinical study to evaluate the immune-enhancing properties of a proprietary larch arabinogalactan (ResistAid™) by assessing the incidence of common cold

onza Ltd (Switzerland)0 个研究点目标入组 200 人开始时间: 2012年6月8日最近更新: 2016年11月7日

适应症

试验速览

暂无简介。

•1. Age 18 - 70 years (child-bearing females had to agree to use appropriate birth control methods)
•2. Recurrent infections of upper airways (at least 3 episodes in half-year according to subject?s statement)
•3. Written consent of the subject to study participation, subject understands the requirements and is willing to comply

•1. Acute infection of the upper airways
•2. Chronic upper airways disease (e.g. chronic bronchitis or asthma)
•3. Suspected influenza or swine flu
•4. Body temperature above 38°C
•5. Vaccination against influenza or swine flu within 21 days before study start
•6. Serious organ or systemic diseases
•7. Body mass index above 30
•8. Clinically significant abnormal laboratory parameters (values outside of reference range)
•9. Known sensitivity to the ingredients of the investigational product
•10. Inborn or acquired immune deficiency disease (e.g. HIV infection)
•11. Pregnancy and nursing
•12. Use of following medication:
•12.1. Immunosuppressive agents
•12.2. Immunostimulating agents, e.g. Echinacea
•12.3. Local oral and pharyngeal treatment
•12.4. Antibiotics within 14 days before study start
•13. Drugs, alcohol and medical abuse
•14. Use of prebiotics and probiotics (e.g. yogurt, drinks, supplements)
•15. Participation in another clinical study at or within 30 days before study start
•16. Inability to comply with study requirements

发起方

onza Ltd (Switzerland)